Skip Navigation

skip navigationNIDDK Home
NIDDK Reference Collection
Diet   Exercise   Health  
Home Page
-  

FAQ

Detailed Search

- -
NIDDK INFORMATION SERVICES
- -

Diabetes

Digestive Diseases

Endocrine and Metabolic Diseases

Hematologic Diseases

Kidney and Urologic Diseases

Weight-control Information Network

-
NIDDK EDUCATION
PROGRAMS

- -

National Diabetes Education Program

National Kidney Disease Education Program

-
- - -
NIDDK Home
-
Contact Us
-
New Search
-
Topic: kidney and urologic diseases (ku)
Title: Drugs Used in the Treatment of Interstitial Cystitis.
Author: Garthwaite, M.; Eardley, I.
Source: IN: Eardley, I., et al, eds. Drug Treatment in Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 62-73.
Availability: Available from Blackwell Publishing Inc. P.O.Box 20, Williston, VT 05495. Phone: 1-800-216-2522. Email: orders@aidcvt.com. Website: http://www.blackwellpublishing.com. Price: $99.95.
Abstract: Interstitial cystitis (IC) is a chronic, debilitating condition that is characterized by urinary frequency and urgency, together with chronic pelvic or perineal pain. This chapter on drugs used in the treatment of IC is from a book that offers a comprehensive summary of the role of pharmacology in urology. After an introductory section that reviews the epidemiology of IC and the impact of this condition on the patient’s quality of life, the authors summarize the principles of therapy for this difficult-to-manage problem. Therapies can be undertaken for urothelial protection, mast cell or histamine release inhibition, immunogenic response modulation, modulation of neurogenic inflammation, and modulation of nociception. Specific drugs discussed including those approved for the treatment of IC: pentosan polysulphate (Elmiron), hyaluronic acid/sodium hyaluronate (Cystistat), and dimethyl sulphoxide (DMSO or RIMSO-50). The author also reviews some of the research into agents that are not yet licensed for treating IC: hydroxyzein, cimetidine, amitriptyline, L-arginine, bacillus Calmette-Guerin, cyclosporin, heparin, misoprostol, and montelukast; a final section briefly considers future developments in this area, including the use of suplatast tosilate, vanilloid receptor antagonists, resiniferatoxin, botulinum toxin, and gene therapy. 1 table. 45 references.

Format: Book Chapter
Language: English.
Major Keywords: Urologic Diseases. Interstitial Cystitis. Drug Therapy. Drug Effects. Pharmacology. Patient Care Management.
Minor Keywords: Patient Selection. Administration and Dosage. Symptoms. Inflammation. Mucosal Tissue. Pain. Bladder.
Publication Number: KUBK11566.
Printer-Friendly Version | Return to Search Results
<-- previous record | next record -->

View NIDDK Publications | NIDDK Health Information | Contact Us

The NIDDK Reference Collection is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
NIDDK Clearinghouses Publications Catalog
5 Information Way
Bethesda, MD 20892–3568
Phone: 1–800–860–8747
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: catalog@niddk.nih.gov

Privacy | Disclaimers | Accessibility | Public Use of Materials
H H S logo - link to U. S. Department of Health and Human Services NIH logo - link to the National Institute of Health NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases